[
    [
        {
            "time": "2018-01-01",
            "original_text": "Why Did JNJ Scrap Its Alzheimer’s Drug Mid-Stage Trial?",
            "features": {
                "keywords": [
                    "JNJ",
                    "Alzheimer’s",
                    "Drug",
                    "Scrap",
                    "Trial"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Why Did JNJ Scrap Its Alzheimer’s Drug Mid-Stage Trial?",
                "Correlation": 8,
                "Sentiment": 3,
                "Importance": 9,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-01-01",
            "original_text": "Amgen's Label Expansion Application for Prolia Gets FDA Nod",
            "features": {
                "keywords": [
                    "Amgen",
                    "Label",
                    "Expansion",
                    "Prolia",
                    "FDA"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "biotechnology"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Amgen's Label Expansion Application for Prolia Gets FDA Nod",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-01-01",
            "original_text": "Eli Lilly’s Elanco in Q1 2018",
            "features": {
                "keywords": [
                    "Eli Lilly",
                    "Elanco",
                    "Q1",
                    "2018"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "animal health"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Eli Lilly’s Elanco in Q1 2018",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 4,
                "Entity_Density": 7,
                "Market_Scope": 3,
                "Time_Proximity": 3,
                "Headline_Structure": 5,
                "Source_Recency": 3
            }
        },
        {
            "time": "2018-01-01",
            "original_text": "Eli Lilly’s Cardiovascular Products in Q1 2018",
            "features": {
                "keywords": [
                    "Eli Lilly",
                    "Cardiovascular",
                    "Products",
                    "Q1",
                    "2018"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "cardiovascular"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Eli Lilly’s Cardiovascular Products in Q1 2018",
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 4,
                "Time_Proximity": 3,
                "Headline_Structure": 5,
                "Source_Recency": 3
            }
        },
        {
            "time": "2018-01-01",
            "original_text": "Lilly's Taltz® (ixekizumab) Receives the First U.S. FDA Approval for Label Update to Include Data for Psoriasis Involving the Genital Area",
            "features": {
                "keywords": [
                    "Lilly",
                    "Taltz",
                    "FDA",
                    "Approval",
                    "Label",
                    "Update",
                    "Psoriasis"
                ],
                "sentiment_score": 0.8,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "dermatology"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Lilly's Taltz® (ixekizumab) Receives the First U.S. FDA Approval for Label Update to Include Data for Psoriasis Involving the Genital Area",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-01-01",
            "original_text": "Eli Lilly’s Oncology Products in Q1 2018",
            "features": {
                "keywords": [
                    "Eli Lilly",
                    "Oncology",
                    "Products",
                    "Q1",
                    "2018"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "oncology"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Eli Lilly’s Oncology Products in Q1 2018",
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 4,
                "Time_Proximity": 3,
                "Headline_Structure": 5,
                "Source_Recency": 3
            }
        },
        {
            "time": "2018-01-01",
            "original_text": "Eli Lilly And Co. To Present At UBS Global Conference; Webcast At 10:30 AM ET",
            "features": {
                "keywords": [
                    "Eli Lilly",
                    "UBS",
                    "Global",
                    "Conference",
                    "Webcast"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Eli Lilly And Co. To Present At UBS Global Conference; Webcast At 10:30 AM ET",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 3,
                "Duration": 3,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-01-01",
            "original_text": "Eli Lilly: FDA Approves Label Update For Taltz - Quick Facts",
            "features": {
                "keywords": [
                    "Eli Lilly",
                    "FDA",
                    "Label",
                    "Update",
                    "Taltz"
                ],
                "sentiment_score": 0.8,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "dermatology"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Eli Lilly: FDA Approves Label Update For Taltz - Quick Facts",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        }
    ]
]